Ann: Appendix 4D and Half Year Report, page-4

would like to know what the external R&D expense consists of.

so with the $6m in February - now approx $10m in bank so that should last 12 months one would suspect - assuming the status quo. But there are income/expenses for Prilocaine and Lidocaine cream, 2.5% coming through hopefully given it was launched in the United States in December 2022.

"This transaction materially strengthened the Group’s Balance Sheet and provides Acrux with the necessaryWorking Capital to fund current development and commercialisation projects, whilst avoiding any imminentrequirement to implement alternate capital raising strategies".

but also noted the comment that reduction in expenses - "Total Operating Expenses declined by $1.569 million (21%) to $5.839 million, relative to the prior corresponding period. This reduction is attributable to the timing of external research and development project expenses which vary throughout the product development cycle depending progress with development of the project". So in effect claytons reduction in expenses due to R&D and in particular external R&D that could ramp up in the next quarter so any increase in income may be offset by increased external R&D?.

TIme will tell i guess.